|Awarded On||August 24, 2018|
|Title||Developing a Clinically Relevant Drug Testing Platform|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Kyuson Yun|
|Cancer Sites||Breast, Colorectal, Lung and Bronchus|
Despite significant advances in detection and treatment of cancer in the last hundred years, most highly malignant cancers remain incurable. A major contributing factor to this failure is the use of suboptimal experimental platform, namely the established cell lines, for drug discovery and validation. Recent studies indicate that human cancers grow in a complex ecosystem that consists of cancer cells and non-cancer cells that constantly communicate and affect each other’s behavior, including responses to anti- cancer treatments. Established cancer cell lines (human cancer cells cultured on plastic dishes for decades) cannot model these complex interactions that affect tumor growth and thera...